3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Withdrawn
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Conditions
Paraparesis, Tropical Spastic
1
Opportunistic Infections
1
Neuritis
1
Leukemia-Lymphoma, Adult T-Cell
1
Inflammation
1
HTLV-I Infections
1
Epstein-Barr Virus Infections
1
Cytomegalovirus Infections
1
Coinfection
1
Acquired Immunodeficiency Syndrome
1
Interventions
Doxorubicin
16
Zidovudine
13
Vincristine
12
Bleomycin
11
Interferon alpha-2
6
Cyclophosphamide
6
Methotrexate
5
Liposomes
5
Leucovorin
5
Dexamethasone
5
tecogalan
4
sargramostim
4
Filgrastim
4
Etoposide
4
Cytarabine
4
Ritonavir
3
Nivolumab
3
Fluorouracil
3
pomalidomide
2
liposomal doxorubicin
2
interferon alfa-n1
2
Watchful Waiting
2
Valganciclovir
2
Tumor Necrosis Factor-alpha
2
Tobacco Use Cessation Devices
2
Thalidomide
2
Surveys and Questionnaires
2
Rituximab
2
Paclitaxel
2
Observation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Acquired Immunodeficiency Syndrome
×
dolutegravir
×
Clear all
NCT04183738
2020-11-10
i2-D²EFT
Kirby Institute
Phase 4
Withdrawn